12.29

0.16% 0.02

Bioventus Inc (BVS)

Overview News Price History Option Chain Financials Discussions Forecast

Bioventus Inc stock is traded at $12.29, with a volume of 225.16K. It is up +0.16% in the last 24 hours and down -6.96% over the past month. Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Previous Close:

$12.27

Open:

$12.38

24h Volume:

225.16K

Relative Volume:

0.48

Market Cap:

$802.06M

Revenue:

$512.35M

Net Income/Loss:

$-156.23M

P/E Ratio:

-2.6834

EPS:

-4.58

Net Cash Flow:

$7.98M

1W Performance:

+7.71%

1M Performance:

-6.96%

6M Performance:

+92.94%

1Y Performance:

+204.96%

1-Day Range:

$12.04

$12.61

1-Week Range:

$11.17

$12.61

52-Week Range:

$3.7987

$14.38

Bioventus Inc Stock (BVS) Company Profile

Name

Bioventus Inc

Sector

Healthcare (1200)

Industry

Medical Devices (153)

Phone

(919) 474-6700

Address

4721 EMPEROR BOULEVARD, SUITE 100, DURHAM

Employee

1,030

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BVS's Discussions on Twitter

Compare BVS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BVS Bioventus Inc	12.29	802.06M	512.35M	-156.23M	7.98M	-4.58
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Bioventus Inc Stock (BVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Mar-15-22	Initiated	Craig Hallum	Buy
Nov-15-21	Resumed	Morgan Stanley	Overweight
Nov-10-21	Resumed	JP Morgan	Overweight
Jul-01-21	Downgrade	Goldman	Buy → Neutral
Mar-08-21	Initiated	Canaccord Genuity	Buy
Mar-08-21	Initiated	Goldman	Buy
Mar-08-21	Initiated	JP Morgan	Overweight
Mar-08-21	Initiated	Morgan Stanley	Overweight

View All

Bioventus Inc Stock (BVS) Latest News

Nov 26, 2024

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.

Nov 26, 2024

Nov 25, 2024

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 258,756 Bioventus Inc. (NYSE:BVS) - MarketBeat

Nov 25, 2024

Nov 23, 2024

Segall Bryant & Hamill LLC Invests $4.52 Million in Bioventus Inc. (NYSE:BVS) - MarketBeat

Nov 23, 2024

Nov 20, 2024

Royce & Associates LP Invests $8.34 Million in Bioventus Inc. (NYSE:BVS) - MarketBeat

Nov 18, 2024

Nov 14, 2024

Los Angeles Capital Management LLC Acquires Shares of 143,464 Bioventus Inc. (NYSE:BVS) - MarketBeat

Nov 14, 2024

Nov 12, 2024